Takeda Pharmaceutical Company, Bay City Capital and Deerfield Management Partner with Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine on Launch of Pioneering Drug Discovery Company Bridge Medicines

November 01, 2016

NEW YORK – Paul Hastings, a leading global law firm, announced today that the firm represented Takeda Pharmaceutical Company Ltd., and healthcare investment firms Bay City Capital and Deerfield Management on the launch of Bridge Medicines, a new drug discovery company.

Launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases. Bridge Medicines will harness the combined strengths of academic discovery, industrial know-how, capital and entrepreneurship, to not only change the paradigm of drug development but also help transform New York into a world-class center of biotechnology excellence.

The Paul Hastings team was led by partners Samuel Waxman and Andrew Short, which also included associates Michael Vargas and Rachel Harrison.

At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms